InnoCare Pharma
ISIN KYG4783B1032
|WKN A2PVC2
Overview
Description
InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. It engages in discovering, developing and commercializing drugs for the treatment of cancer and autoimmune diseases. The company was founded by Jisong Cui and Yigong Shi on November 3, 2015 and is headquartered in Beijing, China.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 1,896.62 m |
| EPS, EUR | -0.03 |
| P/B ratio | 1.89 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 127.71 m |
| Net income, EUR | -56.60 m |
| Profit margin | -44.32% |
What ETF is InnoCare Pharma in?
There are 16 ETFs which contain InnoCare Pharma. All of these ETFs are listed in the table below. The ETF with the largest weighting of InnoCare Pharma is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
